ArticleEndocrinology, diabetes & metabolism case reports2026
PPAR-α activator pemafibrate lowered plasma insulin-like growth factor-1 level in a patient with acromegaly.
Article in Endocrinology, diabetes & metabolism case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- PERSPECTIVE: Beyond the GH-IGF-1 axis: a network perspective integrating clinical observations and mechanistic insights.Endocrine connections · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Summary: This is a report of a patient with acromegaly that was ameliorated by pemafibrate, a peroxisome proliferator-activated receptor-α (PPAR-α) activator. Baseline acromegaly medication for this patient was lanreotide (90 mg/month). A marked reduction in insulin-like growth factor-1 levels was observed after initiating pemafibrate and remained during 12 months of follow-up. PPAR-α agonists might prove useful in pharmacotherapy for acromegaly. Learning points: Pemafibrate was effective for regulating dyslipidemia in the present case. A concomitant decrease in plasma IGF-1 levels was observed following initiation of pemafibrate treatment. Some in vitro studies have described beneficial effects of pemafibrate. Pemafibrate warrants investigation as a new treatment for acromegaly.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.